- Home
- OCUP vs SYRS Comparison
OCUP vs SYRS Comparison
Compare OCUP & SYRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OCUP
- SYRS
- Stock Information
- Founded
- OCUP 2018
- SYRS 2011
- Country
- OCUP United States
- SYRS United States
- Employees
- OCUP N/A
- SYRS 68
- Industry
- OCUP Biotechnology: Pharmaceutical Preparations
- SYRS Biotechnology: Pharmaceutical Preparations
- Sector
- OCUP Health Care
- SYRS Health Care
- Exchange
- OCUP Nasdaq
- SYRS Nasdaq
- Market Cap
- OCUP 53.1M
- SYRS 52.5M
- IPO Year
- OCUP N/A
- SYRS 2016
- Fundamental
- Price
- OCUP $1.32
- SYRS $1.96
- Analyst Decision
- OCUP Strong Buy
- SYRS Strong Buy
- Analyst Count
- OCUP 3
- SYRS 3
- Target Price
- OCUP $18.67
- SYRS $5.00
- AVG Volume (30 Days)
- OCUP 86.6K
- SYRS 357.3K
- Earning Date
- OCUP 11-11-2024
- SYRS 11-12-2024
- Dividend Yield
- OCUP N/A
- SYRS N/A
- EPS Growth
- OCUP N/A
- SYRS N/A
- EPS
- OCUP N/A
- SYRS N/A
- Revenue
- OCUP $16,449,000.00
- SYRS $4,149,000.00
- Revenue This Year
- OCUP N/A
- SYRS N/A
- Revenue Next Year
- OCUP $258.69
- SYRS $614.29
- P/E Ratio
- OCUP N/A
- SYRS N/A
- Revenue Growth
- OCUP N/A
- SYRS N/A
- 52 Week Low
- OCUP $1.15
- SYRS $1.43
- 52 Week High
- OCUP $3.53
- SYRS $8.17
- Technical
- Relative Strength Index (RSI)
- OCUP 48.70
- SYRS 44.14
- Support Level
- OCUP $1.25
- SYRS $1.85
- Resistance Level
- OCUP $1.35
- SYRS $2.03
- Average True Range (ATR)
- OCUP 0.08
- SYRS 0.14
- MACD
- OCUP 0.01
- SYRS 0.08
- Stochastic Oscillator
- OCUP 29.17
- SYRS 27.66
About OCUP Ocuphire Pharma Inc.
Ocuphire Pharma Inc is a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Ocuphire's pipeline includes two small molecular product candidates targeting the front and back of the eye indications. The Nyxol candidate is being developed for dim light or night vision disturbances, reversal of pharmacologically induced mydriasis, and presbyopia. The second product candidate, APX3330, is being developed for diabetic retinopathy and diabetic macular edema.
About SYRS Syros Pharmaceuticals Inc.
Syros Pharmaceuticals Inc is a biopharmaceutical company committed to developing new standards of care for the frontline treatment of patients with hematologic malignancies.